Teva Pharmaceutical Industries Ltd. has received tentative FDA approval for its ANDA (abbreviated new drug application) to market a gastric-acid pump inhibitor. Teva is currently in patent dispute litigation over the product, which is a generic form of TAP Pharmaceutical’s drug Prevacid (Lansoprazole) Delayed-release Capsules, 15 mg and 30 mg.